While keeping eye on snap NASH OK, Inventiva tests out alternative PhIII path

Amber Tong

As promising late-stage data reinvigorate the enthusiasm for NASH drugs after years of setbacks, one player is changing up its Phase III plans to capitalize …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

While keeping eye on snap NASH OK, Inventiva tests out alternative PhIII path

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

While keep­ing eye on snap NASH OK, In­ven­ti­va tests out al­ter­na­tive PhI­II path

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

While keeping eye on snap NASH OK, Inventiva tests out alternative PhIII path

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved